R. D. Hannan

Nuclear stabilisation of p53 requires a functional nucleolar surveillance pathway

This study identifies the nucleolar surveillance pathway (NSP) as a central regulator of p53 stability, showing its role in integrating various cellular stresses and its potential as a therapeutic target in cancer.

Cohesin mutations are synthetic lethal with stimulation of WNT signaling

The paper identifies GSK3 inhibitors as synthetic lethal with cohesin mutations, revealing Wnt pathway activation as a therapeutic target in cohesin mutant cancers.

Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis

The paper shows that combining CX-5461 with pathway inhibitors improves efficacy by suppressing metabolic regulators, but resistance arises through translational re-wiring and cAMP pathway activation in blood cancers.

Targeting RNA Polymerase I transcription synergises with TOP1 inhibition in potentiating the DNA damage response in high-grade serous ovarian cancer

This study identifies that combining RNA Polymerase I inhibitor CX-5461 with TOP1 inhibitor topotecan enhances DNA damage response and efficacy in high-grade serous ovarian cancer.

PGRMC1 phosphorylation and cell plasticity 1: glycolysis, mitochondria, tumor growth

This study shows that altering PGRMC1 phosphorylation in cancer cells affects energy metabolism, mitochondrial function, and tumor growth.

Inhibition of RNA Polymerase I Transcription Activates Targeted DNA Damage Response and Enhances the Efficacy of PARP Inhibitors in High-Grade Serous Ovarian Cancer

This study shows CX-5461, an RNA polymerase I inhibitor, enhances PARP inhibitor efficacy in HR-deficient HGSOC by inducing replication stress and DNA damage, overcoming resistance mechanisms.